Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Enterprise Value (2020 - 2025)

Historic Enterprise Value for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to -$375.5 million.

  • Mirum Pharmaceuticals' Enterprise Value fell 3202.83% to -$375.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$375.5 million, marking a year-over-year decrease of 3202.83%. This contributed to the annual value of -$280.3 million for FY2024, which is 209.94% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Enterprise Value is -$375.5 million, which was down 3202.83% from -$304.6 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Enterprise Value peaked at -$132.1 million during Q1 2023, and registered a low of -$434.9 million during Q3 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' median Enterprise Value value was -$294.7 million (recorded in 2022), while the average stood at -$297.5 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Enterprise Value soared by 6040.22% in 2023, and later tumbled by 12929.97% in 2024.
  • Mirum Pharmaceuticals' Enterprise Value (Quarter) stood at -$256.5 million in 2021, then rose by 1.88% to -$251.7 million in 2022, then decreased by 13.75% to -$286.3 million in 2023, then rose by 2.1% to -$280.3 million in 2024, then plummeted by 33.97% to -$375.5 million in 2025.
  • Its Enterprise Value stands at -$375.5 million for Q3 2025, versus -$304.6 million for Q2 2025 and -$277.7 million for Q1 2025.